Chia-Ta Wu1, Peng-Jung Chen2, Yu-Tzu Lee3, Jiunn-Liang Ko3, Ko-Haung Lue4. 1. Department of Emergency Medicine, Changhua Christian Hospital, Changhua, Taiwan; Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan. 2. School of Public Health, Chung Shan Medical University, Taichung, Taiwan. 3. Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan. 4. Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan; School of Medicine, Chung Shan Medical University, Taichung, Taiwan; Department of Pediatrics, Chung Shan Medical University Hospital, Taichung, Taiwan. Electronic address: cshy095@csh.org.tw.
Abstract
BACKGROUND: Asthma is a common allergic disease. In previous studies, probiotics improved the balance of intestinal microbes, reduced inflammation, and promoted mucosal tolerance. This study investigated whether oral administrations of Lactobacillus rhamnosus GG (LGG) inhibited allergen (ovalbumin or OVA)-induced airway inflammation in a mouse asthma model. METHODS: The allergy/asthma animal model in this study was sensitization with OVA. After intranasal challenge with OVA, the airway inflammation and hyper-responsiveness were determined by a Buxco system, bronchoalveolar lavage fluid analysis with Liu stain, and enzyme-linked immunosorbent assay. Histopathologic changes in the lung were detected by hematoxylin and eosin staining and immunohistochemistry staining. RESULTS: Both pre- and post-treatment with LGG suppressed the airway hyper-responsiveness to methacholine and significantly decreased the number of infiltrating inflammatory cells and Th2 cytokines in bronchoalveolar lavage fluid and serum compared with the OVA-sensitized mice. In addition, LGG reduced OVA-specific IgE levels in serum. Oral LGG decreased matrix metalloproteinase 9 expression in lung tissue and inhibited inflammatory cell infiltration. CONCLUSION: LGG had an anti-inflammatory effect on OVA-induced airway inflammation and might be an additional or supplementary therapy for allergic airway diseases.
BACKGROUND: Asthma is a common allergic disease. In previous studies, probiotics improved the balance of intestinal microbes, reduced inflammation, and promoted mucosal tolerance. This study investigated whether oral administrations of Lactobacillus rhamnosus GG (LGG) inhibited allergen (ovalbumin or OVA)-induced airway inflammation in a mouse asthma model. METHODS: The allergy/asthma animal model in this study was sensitization with OVA. After intranasal challenge with OVA, the airway inflammation and hyper-responsiveness were determined by a Buxco system, bronchoalveolar lavage fluid analysis with Liu stain, and enzyme-linked immunosorbent assay. Histopathologic changes in the lung were detected by hematoxylin and eosin staining and immunohistochemistry staining. RESULTS: Both pre- and post-treatment with LGG suppressed the airway hyper-responsiveness to methacholine and significantly decreased the number of infiltrating inflammatory cells and Th2 cytokines in bronchoalveolar lavage fluid and serum compared with the OVA-sensitized mice. In addition, LGG reduced OVA-specific IgE levels in serum. Oral LGG decreased matrix metalloproteinase 9 expression in lung tissue and inhibited inflammatory cell infiltration. CONCLUSION:LGG had an anti-inflammatory effect on OVA-induced airway inflammation and might be an additional or supplementary therapy for allergic airway diseases.
Authors: Timothy C Borbet; Miranda B Pawline; Xiaozhou Zhang; Matthew F Wipperman; Sebastian Reuter; Timothy Maher; Jackie Li; Tadasu Iizumi; Zhan Gao; Megan Daniele; Christian Taube; Sergei B Koralov; Anne Müller; Martin J Blaser Journal: Mucosal Immunol Date: 2022-07-16 Impact factor: 8.701
Authors: Virginia Perez-Carrasco; Ana Soriano-Lerma; Miguel Soriano; José Gutiérrez-Fernández; Jose A Garcia-Salcedo Journal: Front Cell Infect Microbiol Date: 2021-05-18 Impact factor: 5.293
Authors: Alexander Heldner; Matthew D Heath; Benjamin Schnautz; Sebastian Kotz; Adam Chaker; Matthias F Kramer; Constanze A Jakwerth; Ulrich M Zissler; Carsten B Schmidt-Weber; Simon Blank Journal: Probiotics Antimicrob Proteins Date: 2022-02-03 Impact factor: 4.609
Authors: K A T Verheijden; L E M Willemsen; S Braber; T Leusink-Muis; P V Jeurink; J Garssen; A D Kraneveld; G Folkerts Journal: Eur J Nutr Date: 2015-05-24 Impact factor: 5.614
Authors: D Betty Lew; Christie F Michael; Tracie Overbeck; W Scout Robinson; Erin L Rohman; Jeffrey M Lehman; Jennifer K Patel; Brandi Eiseman; Kim S LeMessurier; Amali E Samarasinghe; M Waleed Gaber Journal: J Immunol Res Date: 2017-08-01 Impact factor: 4.818